1-O-tert-butyl 4-O-(3-carbamoylpentan-3-yl) butanedioate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 1-O-tert-butyl 4-O-(3-carbamoylpentan-3-yl) butanedioate
• 化学式: C₁₄H₂₅NO₅
• 分子量: 287.35
• InChiKey: JDWJITJAINLIFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  20
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  95.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• PROTECTED SUCCINATES FOR ENHANCING MITOCHONDRIAL ATP-PRODUCTION
  申请人：MITOPHARM LTD

  公开号：US20150259317A1

  公开（公告）日：2015-09-17

  Disclosed herein are mono or di-succinate compounds where one or both of the acid groups in the succinate core are protected in the form of biologically labile moieties, and the use of said compounds to enhance mitochondrial function. The compounds may be of formula (I) wherein R 1 is H or an optionally substituted alkyl group or a group of formula (II) and R 2 is independently a group according to formula (II) where formula (II) is as defined 10 herein.

  本文揭示了一种单或二琥珀酸酯化合物，其中琥珀酸核中的一个或两个酸基以生物活性的基团形式得到保护，并且使用该化合物来增强线粒体功能。该化合物可以是式（I）的形式，其中R1为H或可选择取代的烷基或式（II）的基团，R2独立地是式（II）定义的基团，其中式（II）如本文所定义。
• Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to Complex I-related impairment of mitochondrial oxidative phosphorylation
  申请人：NEUROVIVE PHARMACEUTICAL AB

  公开号：US10307389B2

  公开（公告）日：2019-06-04

  The present invention relates to a succinate prodrug for use in the treatment or prevention of lactic acidosis.

  本发明涉及一种用于治疗或预防乳酸中毒的琥珀酸原药。
• Succinate Prodrugs for Use in the Treatment of Lactic Acidosis or Drug-Induced Side-Effects Due to Complex I-Related Impairment of Mitochondrial Oxidative Phosphorylation
  申请人：NEUROVIVE PHARMACEUTICAL AB

  公开号：US20170100359A1

  公开（公告）日：2017-04-13

  The present invention relates to a succinate prodrug for use in the treatment or prevention of lactic acidosis.
• US9670175B2
  申请人：——

  公开号：US9670175B2

  公开（公告）日：2017-06-06
• [EN] PROTECTED SUCCINATES FOR ENHANCING MITOCHONDRIAL ATP-PRODUCTION<br/>[FR] SUCCINATES PROTÉGÉS POUR ACCROÎTRE LA PRODUCTION MITOCHONDRIALE D'ATP
  申请人：MITOPHARM LTD

  公开号：WO2014053857A1

  公开（公告）日：2014-04-10

  Disclosed herein are mono or di-succinate compounds where one or both of the acid groups in the succinate core are protected in the form of biologically labile moieties, and the use of said compounds to enhance mitochondrial function. The compounds may be of formula (I) wherein R1 is H or an optionally substituted alkyl group or a group of formula (II) and R2 is independently a group according to formula (II) where formula (II) is as defined 10 herein.